MB

Marianne Bjørdal

Partner at 3B Future Health Ventures

Greater Nice Metropolitan Area

Investor
VC

Invests in

Stages:

Series A
Seed

Locations:

France

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Life Sciences
Biotechnology
venture capital
Science
Pharmaceutical Industry
Research and Development (R&D)
Project Management
Neuroscience
Business
Project Planning
Genetics
Marketing Strategy
French
English
Norwegian
Drosophila

Education

Investments

Sibylla Biotech

Series A

Total Funding: $23M

Epsilogen

Series B

Total Funding: $47M

GenEp

Seed

Total Funding: $1M

Work Experience

Helsinn Group -3B Future Health Ventures

2018

  • Partner

    2022

  • Senior Associate

    2019 - 2022

  • Investment Analyst

    2018 - 2019

Sibylla Biotech

2022

  • Board Member

    2022

Epsilogen Ltd

2022

  • Board member

    2022

Kither Biotech

2022

  • Board Observer

    2022

GenEp Inc

2021

  • Board member

    2021

NeoPhore Ltd

2021

  • Board member

    2021

Gain Therapeutics

2020 - 2021

  • Board Member

    2020 - 2021

Virbac

2018 - 2018

  • Project Monitor

    2018 - 2018

CNRS

2005 - 2017

  • Researcher

    2012 - 2017

    Neurobiology, genetics, growth, metabolism and development

  • PhD fellow

    2005 - 2011

    Marie Curie Early Stage Researcher

Norges forskningsråd

2006 - 2011

  • PhD fellow

    2006 - 2011